Ridge's list of big winners for next year, page-40

Epitan(EPT)

EpiTan Limited (ASX:EPT) today announced it had received Ethics
Committee approval from Sydney's Royal Prince Alfred Hospital to
commence Phase IIb trials on its tanning drug, Melanotan.

The Phase IIb trial will be carried out by Professor Ross Barnetson,
a world authority in the field of photobiology, ultraviolet skin
damage and the immunology of skin tumours. Royal Prince Alfred
Hospital is a leading hospital in Australia for clinical research.

The trial will determine the ability of Melanotan to reduce the
degree and toxicity of sunburn in approximately 80 healthy volunteers
exposed to ultraviolet light both before and after a regime of
Melanotan. The drug will be administered daily for 10 days in each of
three consecutive months. Twenty volunteers will receive placebos.

It is planned that the study will commence in the next month and will
take around eight months to complete.

Now tell me who doesn't want a suntan?
Cheers Ralph